Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Opens New Euro Headquarters in Cambridge

This article has been updated from a previous version.

NEW YORK, July 19 - Accelrys today said it has opened its new European headquarters.

The new base, in Cambridge, UK, will consolidate staff from Accelrys' facilities already in that city as well as in Leeds and Oxford. These facilities will be shuttered when their staff finishes moving into the new space, scheduled to happen before the end of the quarter, according to an Accelrys spokesman.

According to Accelrys, a unit of drug discoverer Pharmacopoeia, the 42,000-square-foot space will be home to the company's European product-development staff, sales and marketing departments, finance, and administration.

Accelrys will also use a portion of the space to hold scientific conferences and seminars, the company said.

The spokesman, Jim Rivas, said their were no layoffs as a result of the move.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.